Eisai Co., Ltd.
https://www.eisai.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
AC Immune and J&J Advance Tau-Targeting Alzheimer’s Vaccine
AC Immune has seen two big disappointments in its Alzheimer’s pipeline this year, but its partner Johnson & Johnson has put its faith in a novel vaccine-like approach to targeting the disease.
How Much Amyloid Clearance, How Fast Is Needed To Slow Alzheimer’s?
Lilly’s donanemab showed faster, deeper amyloid clearance versus Biogen/Eisai’s Aduhelm and Roche’s failed Phase III gantenerumab studies showed the importance of deep, rapid removal.
Lecanemab Data On Benefit In Alzheimer’s Might Satisfy FDA – But What About Medicare?
Centers for Medicare and Medicaid Services’ standard for determining whether drugs produce a clinically meaningful improvement in cognition that would allow for broader Medicare coverage is unclear. But Eisai/Biogen’s lecanemab is likely to serve as a first test.
Lilly CEO: Realistic Expectations Needed For Current Wave of Alzheimer’s Treatments
Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.
Company Information
- Industry
- Distributors
- Pharmaceuticals
- Other Names / Subsidiaries
-
- EA Pharma Co., Ltd.
- Eisai China Inc
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Jingyi Weixiang (Shanghai) Health Industry Development Limited
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.